Document is current

Article History

Received: 19 April 2024

Accepted: 11 September 2024

First Online: 30 September 2024

Declarations

:

: The two prospective studies were conducted in accordance with the declaration of Helsinki and approved by the local Scientific Ethical Committee (H-20028894, H-19025674), the Danish Medical Agency (2020–001173-69) and the Danish Data Protection Agency (P-2020–309, P-2020–847). A signed informed consent form was required to participate.

: Not applicable.

: The authors disclose the following: H.J.N.L. and P.R. received QFT assays from SSI Diagnostica for the study. SSI Diagnostica had no role in the planning, analysis or dissemination of the study. FKK has served on scientific advisory panels and/or been part of speaker's bureaus for, served as a consultant to and/or received research support from, and/or has shares in, Antag Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Gubra, Novo Nordisk, Sanofi, Zealand Pharma and is currently employed by Novo Nordisk. P.R. has a patent on IP-10 as a diagnostic tool for TB. The remaining authors have nothing to disclose and all authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.